… rational use of chinese medicine in our lives.
shanghanlun
Uses of Minor Green-Blue Dragon Decoction
The idea is this: a person has exterior signs and is dripping like a tap. This tells us he has 小青龙-type fluids inside). Cold has caused his to cough, pant or even wheeze.
小青龙汤 can be used either for:
- plain cough: with white, transparent, bubbly phelgm (the stuff we see). This is very similar to 金匮要略’s “痰饮,” which is actually “淡饮.” Best described in chinese as “落地成水”.
- bronchitis (inflammation of the bronchial tubes): where excessive secretions as well as bronchial spasms cause breathing problems.
Still, keep a lookout for the 小青龙汤-type person.
Popularity: 8% [?]
Often used for allergic rhinitis where the snot and phlegm is clear and running. It’s 痰饮 after all.
[...] way, it makes sense to think of 小青龙汤 as an catarrh inflammation antidote, or even as a form of antihistamine treatment, albeit more [...]
Sho-seiryu-to is the kampo medicine name of xiaoqinglong decoction.
In a double-blind, placebo-controlled trial used on patients with atopic ecema, carried out in London’s Hospital for Sick Children, there was significant reduction of erythema (skin redness caused by capillary congestion) and surface area, while the blood tests, renal and hepatic tests appeared normal.
Called So-Cheong-Ryong-Tang (SCRT) in Traditional Korean Medicine: According to some korean researchers, this decoction “has been used for treating allergic diseases, such as allergic rhinitis and asthma, for hundreds of years in Asian countries. CD4+ T cells were highly purified by using magnetic bead from splenocytes of BALB/c mice. SCRT treatment slightly decreased the expression of cell surface protein CD69 on CD4+ T cell in the flow cytometry analysis. In RT-PCR analysis, SCRT increases the expression of IL-2 and IL2R-alpha mRNA, and decreases the expression of IL-4 mRNA, which is an important cytokine of Th2 cell development. On the other hand, SCRT treatment increases IFN-gamma expression, which is one of the key cytokines for Th1 cell development. Present study implies that SCRT can correct Th2 dominant condition directly affecting to the CD4+ T cell without significantly depressing general T cell activities. These results also suggest that the effect on CD4+ T cell may be the one of key pharmacological effect point for treating IgE medicated allergic asthma by SCRT.”
It is also anti-influenza: ” The Kampo (Japanese herbal) medicine, Sho-seiryu-to, which has traditionally been used for the treatment of colds and bronchial asthma, showed potent antiinfluenza A and B virus activity through augmentation of production of antiviral IgA antibody in the nasal and bronchoalveolar cavities of mice when administrated orally before viral infection. Sho-seiryu-to also showed antiinfluenza virus activity against A virus H1N1 subtype infected in aged mice (approximately 6 months old) with an increase of antiviral IgA antibody in the bronchoalveolar wash of the treated mice by similar administration. When mice infected with mouse nonadapted influenza A virus H3N2 subtype before 14 days were secondarily infected with mouse adapted A/PR/8 (H1N1) virus and administered Sho-seiryu-to orally after the second infection, replication of the virus in both nasal and bronchoalveolar cavities was significantly inhibited. Sho-seiryu-to had no effect on the mice which were not primed with mouse nonadapted virus when administered after the infection of mouse-adapted A/PR/8 virus. Oral administration of Sho-seiryu-to caused increment of viral-specific IgA antibody secreting cells in mouse nasal lymphocyte. Sho-seiryu-to also augmented IL-2 receptor beta chain+ T-cells in Peyer’s patch of the infected mice. Sho-seiryu-to also significantly reduced viral titer in the nasal washes of the infected ovalbumin-sensitized bronchial asthma model mice. Oral administration of Sho-seiryu-to before and after vaccination significantly augmented hemagglutination-inhibiting antibody in the serum by nasal inoculation of influenza HA vaccine, and significantly augmented nasal antiviral IgA antibody and bronchoalveolar and serum antiviral IgG antibodies even after secondary vaccination although induction of antiviral antibody by intranasal vaccination was insufficient without Sho-seiryu-to. These results suggest that Sho-seiryu-to is able to prevent influenza virus infection by cross-protection of subtypes of influenza A virus and B virus. Sho-seiryu-to is also useful for the treatment of influenza virus infection in hosts with a history of influenza virus infection and/or influenza vaccination and allergic pulmonary inflammation, such as bronchial asthma, and can be used as an adjuvant to nasally inoculated influenza HA vaccine.”
and finally a reference at wellness.com: http://www.wellness.com/reference/healthwellness/sho-seiryu-to-tj-19/
I’ve been searching for this exact info on this subject for a while. Bookmarked and recommended!